The global pericarditis therapeutics industry sales is projected to be worth US$ 3.60 billion in 2022 and US$ 6 billion by 2032, with a compound annual growth rate of 5.24%. The ageing of the population is expected to drive growth in this sector. The need for pericarditis medications will soar due to significant advancements in …